Healthcare solutions firm Indegene Pvt. Ltd said it is raising $200 million from US-based investment firms Carlyle Group and Brighton Park Capital to boost acquisitions and drive global expansion plans.
Carlyle and Brighton Park Capital will pick minority stakes in Indegene through a primary investment along with a secondary sale by existing shareholders and early investors of the Bengaluru-based company. The transaction is awaiting regulatory approvals.
Post-covid, digitization has become a significant part of pharma firms, Gupta said. “We have an opportunity to create a billion-dollar revenue company out of India,” he said.
Indegene, which has clocked seven acquisitions overseas of late, helps life sciences companies with digitizing their sales and marketing functions, enabling filings through content automation, data and analytics capabilities.
“We have been impressed by the strong entrepreneurial energy of the management team at Indegene and their technology-led, data-driven, differentiated global delivery model, as well as by their ability to scale relationships with global healthcare enterprises. We look forward to leveraging our global healthcare network and capabilities to help the company further strengthen and expand its portfolio while deepening relationships with its global client base,” said Neeraj Bharadwaj, MD of the Carlyle Asia advisory team.
Carlyle’s India investments include Piramal Pharma, Sequent Scientific Ltd, Medanta Medicity Hospital and diagnostic centre Metropolis Healthcare. Globally, Carlyle has invested over $13 billion equity in the healthcare sector as of September 2020.
Mark Dzialga, managing partner of Brighton Park Capital said: “With a strong technology platform and a digital-first approach, Indegene has established a reputation for high-quality content, analytics, and other healthcare solutions provided through a seamlessly integrated system.”
This article was first published in livemint.